|Innovative Mass Spectrometry Technology for the Identification of Cancer Immunotherapeutics
|Mon 8:10 AM - Plenary Session
|Donald F. Hunt
University of Virginia
|View Long Abstract
|Adoptive T-cell therapy (ACT) is the most effective treatment for metastatic melanoma. Tumor-infiltrating lymphocytes (TIL) are isolated from resected tumor, expanded ex vivo and then given back to the patient. Objective and complete responses for this therapy in a recent clinical trial of 25 late stage patients with metastatic melanoma were 72% and 16%, respectively. Reported here are the results of research to identify class I phosphopeptide antigens that are presented as a result of dysregulated signal transduction pathways in cancer cells. These antigens should make it possible to employ adoptive T-cell therapy for many additional human cancers.